OrbiMed

Ikena Oncology, Inc. is a biotechnology company focused on discovering and developing biomarker-driven therapies for cancer treatment. It specializes in precision oncology by targeting pathways essential for cancer growth and therapeutic resistance, particularly within the Hippo and RAS signaling networks. The company's portfolio includes several preclinical and discovery-stage programs, such as IK-007, an EP4 receptor antagonist; IK-175, an AHR antagonist; and IK-412, a kynurenine-degrading enzyme. Additionally, Ikena is developing IK-930, an oral small-molecule inhibitor of the TEAD transcription factor involved in the Hippo pathway. Ikena Oncology, originally founded as Kyn Therapeutics in 2016, rebranded in December 2019 and is headquartered in Boston, Massachusetts. The company aims to address significant medical needs in oncology through innovative drug development.

Scorpion Therapeutics, Inc. is a biotechnology company based in Boston, Massachusetts, focused on developing next-generation precision oncology technologies for cancer treatment. Founded in 2020, the company specializes in creating targeted small-molecule drugs that interact with validated cancer targets. Its research encompasses therapies aimed at known oncogenes, previously undruggable cancer targets, and novel targets. By integrating technologies across target discovery, medicinal chemistry, and translational medicine, Scorpion Therapeutics aims to advance a comprehensive pipeline of optimized compounds. The company's goal is to expand the reach of precision medicine, enabling healthcare professionals to offer innovative treatments to a broader range of cancer patients.

Scorpion Therapeutics, Inc. is a biotechnology company based in Boston, Massachusetts, focused on developing next-generation precision oncology technologies for cancer treatment. Founded in 2020, the company specializes in creating targeted small-molecule drugs that interact with validated cancer targets. Its research encompasses therapies aimed at known oncogenes, previously undruggable cancer targets, and novel targets. By integrating technologies across target discovery, medicinal chemistry, and translational medicine, Scorpion Therapeutics aims to advance a comprehensive pipeline of optimized compounds. The company's goal is to expand the reach of precision medicine, enabling healthcare professionals to offer innovative treatments to a broader range of cancer patients.

Ikena Oncology, Inc. is a biotechnology company focused on discovering and developing biomarker-driven therapies for cancer treatment. It specializes in precision oncology by targeting pathways essential for cancer growth and therapeutic resistance, particularly within the Hippo and RAS signaling networks. The company's portfolio includes several preclinical and discovery-stage programs, such as IK-007, an EP4 receptor antagonist; IK-175, an AHR antagonist; and IK-412, a kynurenine-degrading enzyme. Additionally, Ikena is developing IK-930, an oral small-molecule inhibitor of the TEAD transcription factor involved in the Hippo pathway. Ikena Oncology, originally founded as Kyn Therapeutics in 2016, rebranded in December 2019 and is headquartered in Boston, Massachusetts. The company aims to address significant medical needs in oncology through innovative drug development.

Ikena Oncology, Inc. is a biotechnology company focused on discovering and developing biomarker-driven therapies for cancer treatment. It specializes in precision oncology by targeting pathways essential for cancer growth and therapeutic resistance, particularly within the Hippo and RAS signaling networks. The company's portfolio includes several preclinical and discovery-stage programs, such as IK-007, an EP4 receptor antagonist; IK-175, an AHR antagonist; and IK-412, a kynurenine-degrading enzyme. Additionally, Ikena is developing IK-930, an oral small-molecule inhibitor of the TEAD transcription factor involved in the Hippo pathway. Ikena Oncology, originally founded as Kyn Therapeutics in 2016, rebranded in December 2019 and is headquartered in Boston, Massachusetts. The company aims to address significant medical needs in oncology through innovative drug development.

resTORbio, Inc. was a clinical-stage biopharmaceutical company based in Boston, Massachusetts, dedicated to developing novel therapeutics for aging-related diseases. The company focused on inhibiting the target of rapamycin complex 1 (TORC1), a pathway linked to the decline in various organ functions associated with aging. Its lead drug candidate, RTB101, is an oral, selective inhibitor of TORC1, which was undergoing Phase 1b/2a clinical trials for the treatment of Parkinson’s disease and neurodegenerative conditions. Additionally, resTORbio collaborated with TrialSpark to explore RTB101's potential for treating COVID-19. Founded in 2016, the company aimed to address a range of aging-related health issues, including cancer, heart disease, and diabetes. In September 2020, resTORbio was acquired by Adicet Bio, Inc. in a reverse merger transaction.

Gelesis, Inc. is a biotechnology company based in Boston, Massachusetts, focused on developing innovative therapies for gastrointestinal-related chronic diseases, particularly obesity and its associated conditions. The company utilizes a mechanobiology technology platform to create its lead product, Gelesis100, an orally administered smart pill that contains hydrogel particles. This product is designed to expand in the stomach, promoting a feeling of fullness and aiding in weight management. Gelesis also offers PLENITY, an FDA-cleared product that assists individuals with weight management. In addition to these offerings, Gelesis has a pipeline of potential therapeutics targeting conditions such as Type 2 diabetes, non-alcoholic fatty liver disease, and chronic idiopathic constipation. Established in 2006, Gelesis aims to provide safe and effective solutions for patients dealing with obesity and related health issues.